Watchlist Price Alert

Novo Nordisk A/S (NVO)

NYSE: NVO · Real-Time Price · USD

69.06

-0.17 (-0.25%)

At close: May 05, 2025, 3:59 PM

69.34

0.40%

After-hours: May 05, 2025, 08:00 PM EDT

-0.25% (1D)

Bid	69.2
Market Cap	305.57B
Revenue (ttm)	290.4B
Net Income (ttm)	100.99B
EPS (ttm)	3.43
PE Ratio (ttm)	20.14
Forward PE	1.82
Analyst	Buy

Ask	69.35
Volume	8,153,143
Avg. Volume (20D)	10,632,487.2
Open	69.17
Previous Close	69.23
Day's Range	68.89 - 69.79
52-Week Range	57.00 - 148.15
Beta	0.25

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Apr 30, 1981

Employees 76,302

Stock Exchange NYSE

Ticker Symbol NVO

Website https://www.novonordisk.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for NVO stock is "Buy." The 12-month stock price forecast is $160, which is an increase of 131.67% from the latest price.

Stock Forecasts

Next Earnings Release

Novo Nordisk A/S is scheduled to release its earnings on May 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 days ago

+5.53%

Novo Nordisk shares are trading higher after Healt... Unlock content with Pro Subscription

6 days ago

+4.06%

Novo Nordisk shares are trading higher after the company announced Wegovy partnerships with Hims and LifeMD.

News

1 day ago · youtube.com

HIMS Earnings Ahead: Wegovy Offers Upside, Analysts Advise Caution

"There's a sense of caution" heading into Hims & Hers (HIMS) earnings, says Caroline Woods. The telehealth company is up over 65% so far in 2025 but has fallen more than 40% off its February highs.

16 hours ago · zacks.com

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

19 hours ago · fool.com

3 No-Brainer Stocks to Buy in May

Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the sum...

2 days ago · seekingalpha.com

Eli Lilly: Don't Overthink This Buying Opportunity

Eli Lilly faced a 12% drop due to CVS formulary changes favoring Novo Nordisk, but I explain why this seems overstated. Lilly has gained control as the US market leader for GLP-1 drugs, and is still m...

3 days ago · wsj.com

Novo Nordisk: FDA Accepts New Drug Application for Oral Wegovy

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management.

3 days ago · reuters.com

U.S. FDA accepts Novo Nordisk's application for oral Wegovy

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for the experimental once-daily oral version of its blockbuster weight-loss drug Wegovy, the Danish drugmaker sa...

4 days ago · benzinga.com

Why Is Novo Nordisk Stock Trading Higher On Friday?

Novo Nordisk A/S' NVO Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg...

4 days ago · fool.com

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that...